SABS
SAB Biotherapeutics, Inc.- Healthcare
- Biotechnology
- $310M market cap
Forecast run · Sep 14, 2026Upside rank 1111 of 3,136
Model Signal
ForecastQ Daily Probabilities
42.9%
32.9%
26.4%
Analyst Consensus
Recommendation2.13/5 Buy
Last price$3.41
Price target$11.33
Implied move+232.3%
Analysts8
ForecastQ Portfolios
SABS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.